Compare New York Times Co (NYT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs TG Therapeutics Inc — how do they compare? New York Times Co trades at $66.6 (market cap $10.96B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: New York Times Co is the larger of the two by market cap, and New York Times Co pays a 1.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NYT | TGTX | |
|---|---|---|
Market Cap | $10.96B | $8.53B |
Sector | Media | Health |
52-Week High | $85.86 | $59.06 |
52-Week Low | $54.66 | $26.94 |
Enterprise Value | $10.36B | $8.74B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $67.96, up 1.01% today, with a neutral technical signal and mixed moving averages. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.69 exceeding the $0.663 forecast. Revenue growth is steady, rising from $2.3B in 2022 to $2.8B in 2025, with net profit margins improving to 12.17%. The company maintains strong cash flow from operations at $584.49M in 2025. Analyst consensus is a $76.00 price target, though the majority recommend Hold.
Outlook remains cautiously optimistic given earnings momentum and solid fundamentals, but risks include the ongoing OpenAI copyright lawsuit and competitive pressures in digital media. The stock offers potential upside to the consensus target, supported by institutional buying interest, though sentiment is tempered by regulatory and litigation uncertainties.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
